{"id":19990,"date":"2024-12-27T17:06:06","date_gmt":"2024-12-27T09:06:06","guid":{"rendered":"https:\/\/flcube.com\/?p=19990"},"modified":"2024-12-27T17:25:55","modified_gmt":"2024-12-27T09:25:55","slug":"astrazeneca-china-announces-structural-adjustments-to-oncology-business-divisions","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=19990","title":{"rendered":"AstraZeneca China Announces Structural Adjustments to Oncology Business Divisions"},"content":{"rendered":"\n

UK major AstraZeneca\u2019s (AZ, NASDAQ: AZN<\/a>) China unit has announced a new round of structural adjustments, effective January 1, 2025. The oncology business will be reorganized into four distinct divisions: the lung cancer business division, the urogynecology and digestive cancer business division, the breast cancer business division, and the blood tumor business division. These divisions will operate independently while maintaining cooperative relationships. Additionally, the marketing development and sales teams will undergo changes, including the merger and integration of the sales teams for Imfinzi (durvalumab) focused on liver, gallbladder, and lung cancers.<\/p>\n\n\n\n

Executive Changes Accompanying the Reorganization<\/strong>
As part of this restructuring, AstraZeneca China has also made adjustments to its executive team. Zhang Lingyan, the current vice president of AstraZeneca China and head of the oncology business for the lung cancer and digestive tumor business units, will transition to lead the urology and digestive tumor business unit. She will serve as vice president of AstraZeneca China and head of the urology and digestive tumor business unit. Meanwhile, Guan Dongmei, the general manager of AstraZeneca China\u2019s tumor business, will temporarily take charge of the breast cancer business department.<\/p>\n\n\n\n

Recent Changes in Oncology Team Structure<\/strong>
Earlier this year, AstraZeneca China spun off and adjusted its county oncology team in July, integrating it into the lung cancer division and the urology, gynecology, and women’s oncology division. Two months later, the omni-channel division was incorporated into its China biopharmaceutical business unit (BBU), reflecting the company\u2019s ongoing efforts to streamline operations and enhance its focus on oncology.<\/p>\n\n\n\n

Legal Issues Involving Former Executive<\/strong>
In a related development, Leon Wang, AstraZeneca\u2019s former international chief, has been officially arrested on suspicion of smuggling ordinary goods and items, raising concerns about corporate governance within the organization.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

UK major AstraZeneca\u2019s (AZ, NASDAQ: AZN) China unit has announced a new round of structural…<\/p>\n","protected":false},"author":1,"featured_media":19991,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[770,871],"class_list":["post-19990","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-az","tag-nasdaq-azn"],"yoast_head":"\nAstraZeneca China Announces Structural Adjustments to Oncology Business Divisions - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"UK major AstraZeneca\u2019s (AZ, NASDAQ: AZN) China unit has announced a new round of structural adjustments, effective January 1, 2025. The oncology business will be reorganized into four distinct divisions: the lung cancer business division, the urogynecology and digestive cancer business division, the breast cancer business division, and the blood tumor business division. These divisions will operate independently while maintaining cooperative relationships. Additionally, the marketing development and sales teams will undergo changes, including the merger and integration of the sales teams for Imfinzi (durvalumab) focused on liver, gallbladder, and lung cancers.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=19990\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca China Announces Structural Adjustments to Oncology Business Divisions\" \/>\n<meta property=\"og:description\" content=\"UK major AstraZeneca\u2019s (AZ, NASDAQ: AZN) China unit has announced a new round of structural adjustments, effective January 1, 2025. The oncology business will be reorganized into four distinct divisions: the lung cancer business division, the urogynecology and digestive cancer business division, the breast cancer business division, and the blood tumor business division. These divisions will operate independently while maintaining cooperative relationships. Additionally, the marketing development and sales teams will undergo changes, including the merger and integration of the sales teams for Imfinzi (durvalumab) focused on liver, gallbladder, and lung cancers.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=19990\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-27T09:06:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-27T09:25:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/122717.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"540\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19990#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19990\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca China Announces Structural Adjustments to Oncology Business Divisions\",\"datePublished\":\"2024-12-27T09:06:06+00:00\",\"dateModified\":\"2024-12-27T09:25:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19990\"},\"wordCount\":302,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19990#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/122717.png\",\"keywords\":[\"AZ\",\"NASDAQ: AZN\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19990#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19990\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=19990\",\"name\":\"AstraZeneca China Announces Structural Adjustments to Oncology Business Divisions - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19990#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19990#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/122717.png\",\"datePublished\":\"2024-12-27T09:06:06+00:00\",\"dateModified\":\"2024-12-27T09:25:55+00:00\",\"description\":\"UK major AstraZeneca\u2019s (AZ, NASDAQ: AZN) China unit has announced a new round of structural adjustments, effective January 1, 2025. The oncology business will be reorganized into four distinct divisions: the lung cancer business division, the urogynecology and digestive cancer business division, the breast cancer business division, and the blood tumor business division. These divisions will operate independently while maintaining cooperative relationships. Additionally, the marketing development and sales teams will undergo changes, including the merger and integration of the sales teams for Imfinzi (durvalumab) focused on liver, gallbladder, and lung cancers.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19990#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19990\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19990#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/122717.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/122717.png\",\"width\":1080,\"height\":540,\"caption\":\"AstraZeneca China Announces Structural Adjustments to Oncology Business Divisions\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19990#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca China Announces Structural Adjustments to Oncology Business Divisions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca China Announces Structural Adjustments to Oncology Business Divisions - Insight, China's Pharmaceutical Industry","description":"UK major AstraZeneca\u2019s (AZ, NASDAQ: AZN) China unit has announced a new round of structural adjustments, effective January 1, 2025. The oncology business will be reorganized into four distinct divisions: the lung cancer business division, the urogynecology and digestive cancer business division, the breast cancer business division, and the blood tumor business division. These divisions will operate independently while maintaining cooperative relationships. Additionally, the marketing development and sales teams will undergo changes, including the merger and integration of the sales teams for Imfinzi (durvalumab) focused on liver, gallbladder, and lung cancers.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=19990","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca China Announces Structural Adjustments to Oncology Business Divisions","og_description":"UK major AstraZeneca\u2019s (AZ, NASDAQ: AZN) China unit has announced a new round of structural adjustments, effective January 1, 2025. The oncology business will be reorganized into four distinct divisions: the lung cancer business division, the urogynecology and digestive cancer business division, the breast cancer business division, and the blood tumor business division. These divisions will operate independently while maintaining cooperative relationships. Additionally, the marketing development and sales teams will undergo changes, including the merger and integration of the sales teams for Imfinzi (durvalumab) focused on liver, gallbladder, and lung cancers.","og_url":"https:\/\/flcube.com\/?p=19990","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-12-27T09:06:06+00:00","article_modified_time":"2024-12-27T09:25:55+00:00","og_image":[{"width":1080,"height":540,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/122717.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=19990#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=19990"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca China Announces Structural Adjustments to Oncology Business Divisions","datePublished":"2024-12-27T09:06:06+00:00","dateModified":"2024-12-27T09:25:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=19990"},"wordCount":302,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=19990#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/122717.png","keywords":["AZ","NASDAQ: AZN"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=19990#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=19990","url":"https:\/\/flcube.com\/?p=19990","name":"AstraZeneca China Announces Structural Adjustments to Oncology Business Divisions - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=19990#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=19990#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/122717.png","datePublished":"2024-12-27T09:06:06+00:00","dateModified":"2024-12-27T09:25:55+00:00","description":"UK major AstraZeneca\u2019s (AZ, NASDAQ: AZN) China unit has announced a new round of structural adjustments, effective January 1, 2025. The oncology business will be reorganized into four distinct divisions: the lung cancer business division, the urogynecology and digestive cancer business division, the breast cancer business division, and the blood tumor business division. These divisions will operate independently while maintaining cooperative relationships. Additionally, the marketing development and sales teams will undergo changes, including the merger and integration of the sales teams for Imfinzi (durvalumab) focused on liver, gallbladder, and lung cancers.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=19990#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=19990"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=19990#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/122717.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/122717.png","width":1080,"height":540,"caption":"AstraZeneca China Announces Structural Adjustments to Oncology Business Divisions"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=19990#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca China Announces Structural Adjustments to Oncology Business Divisions"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/122717.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19990","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19990"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19990\/revisions"}],"predecessor-version":[{"id":19997,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19990\/revisions\/19997"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/19991"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19990"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19990"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19990"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}